Celltrion reported on Monday that its chronic spontaneous urticaria and allergic asthma treatment, Omlyclo (active ingredient: omalizumab), is rapidly gaining market share across Europe through expanded prescriptions and successful bids.
In Italy, one of the five major European markets (EU5), Omlyclo continues to secure successful bids. Out of 14 state-level omalizumab tenders, Celltrion’s Italian subsidiary has won contracts in 10 regional government auctions.
The UK market has seen notable success with National Health Service (NHS) bids. Celltrion’s UK subsidiary clinched all NHS tenders in four administrative regions, including England, which boasts the largest omalizumab market.
Omlyclo is also making waves in Germany, where it’s quickly establishing a strong market presence. Celltrion stated that since its launch last September, Omlyclo achieved double-digit market share within just one month and continues to show steep growth.
Northern Europe is also seeing tangible results from Omlyclo prescriptions. In Denmark, where Celltrion won a national tender, the company managed to launch Omlyclo four months ahead of schedule through close collaboration with the bidding agency. It has also secured exclusive supplier status until September this year.
Spain and the Netherlands are experiencing ongoing expansion in Omlyclo prescriptions. In Spain, the product was named the primary supplier in all public healthcare tenders for key regions, including Catalonia and the Basque Country.
Celltrion attributes Omlyclo’s European success to product competitiveness, supply stability, and targeted marketing efforts.
Hoon Hae-tae, head of Celltrion’s European operations, stated that from its initial launch, Omlyclo has consistently secured bids and expanded prescriptions across various European countries, showcasing the effectiveness of Celltrion’s sales and marketing strategies. It aims to further extend the reach by continuously expanding into new sales territories throughout Europe.
